Surgery Websites
LiverSource »  Faculty »  Medical Oncology »  Emily Bergsland, M.D.
Emily Bergsland, M.D.

Emily Bergsland, M.D.

  • Professor of Clinical Medicine
  • Division of Hematology Oncology
  • Department of Medicine
  • Ernest Rosenbaum, MD Endowed Chair of Medical Oncology
Open Popup

UniversUniversity of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
University of Minnesota, M.D., 1982

  • 1989-92, Intern, Dept. of Medicine, University of California San Francisco
  • 1990-92, Resident, Dept. of Medicine, University of California San Francisco
  • 1992-92, Chief Resident and Assistant Chief of the Medical Service, Dept. of Medicine, University of California San Francisco
  • 1993-92, Fellow, Medical Oncology, University of California San Francisco
  • 1994-1992, Research Fellow (P I: Douglas Hanahan, Ph.D.), Department of Biochemistry and Biophysics, University of California San Francisco
  • American Board of Internal Medicine
  • American Board of Internal Medicine: Medical Oncology - Subspecialty
  • Colon Cancer
  • Esophageal Cancer
  • Liver Cancer
  • Lynch Syndrome
  • Pancreatic Cancer
  • Rectal Cancer
  • Stomach Cancer
  • Angiogenesis Inhibitors
  • Colorectal Neoplasms
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms
  • Vascular Endothelial Growth Factor

Dr. Emily Bergsland is currently a Professor of Clinical Medicine and holds the Ernest Rosenbaum, MD Endowed Chair of Medical Oncology. She received her medical degree from the University of Minnesota and completed an internship, residency, and chief residency in internal medicine at UCSF. She subsequently completed a fellowship in Medical Oncology and was a Molecular Medicine fellow before joining the UCSF faculty in 1998.

Dr. Bergsland has led numerous clinical studies in patients with gastrointestinal malignancies. Her current efforts are focused on clinical and translational research related to neuroendocrine tumors. At a national level, Dr. Bergsland is a member of the Neuroendocrine Tumor Task force for the National Cancer Institute and a member of the NCCN NET guidelines panel. She is also the study chair for a national study of a novel treatment for patients with carcinoid tumors performed by the ALLIANCE for Clinical Trials and funded by the National Cancer Institute.

Bergsland And Nakakura

Data provided by UCSF Profiles, powered by CTSI
  • UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology
    Sponsor ID:
    Funding Period:
    Jul 2021
    Jun 2026
    Principal Investigator
Data provided by UCSF Profiles, powered by CTSI
Data provided by UCSF Profiles, powered by CTSI
  1. Sada A, Foster TR, Al-Ward R, Sawani S, Charchar H, Pishdad R, Ben-Shlomo A, Dy BM, Lyden ML, Bergsland E, Jasim S, Raj N, Shank JB, Hamidi O, Hamrahian AH, Chambô JL, Srougi V, Fragoso MC, Graham PH, Habra MA, Bancos I, McKenzie TJ. The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study. Surgery. 2023 Nov 08. View in PubMed
  2. Mulvey CK, Paciorek A, Moon F, Steiding P, Shih B, Gubens MA, Zhang L, Bergsland EK, Cheng I. Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors. Endocr Relat Cancer. 2023 Oct 01. View in PubMed
  3. Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol. 2023 Nov 10; 41(32):5049-5067. View in PubMed
  4. Majmudar S, Graff SL, Kays M, Braz BX, Matt-Amaral L, Markham MJ, Subbiah IM, Bergsland E, Jain S. The Careers and Professional Well-Being of Women Oncologists During the COVID-19 Pandemic: Responding for Tomorrow. J Med Internet Res. 2023 08 21; 25:e47784. View in PubMed
  5. Varghese DG, Del Rivero J, Bergsland E. Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel). 2023 Jul 21; 15(14). View in PubMed
  6. View All Publications


Site Directory